Resmed Inc (RMD) Company Profile

ResMed Inc. designs, manufactures, and sells medical devices and software for treating sleep-related breathing disorders, primarily sleep apnea. Its core products are CPAP (Continuous Positive Airway Pressure) machines and masks, which are prescribed to patients to keep airways open during sleep. The company's customers are primarily healthcare providers (Durable Medical Equipment suppliers, hospitals) and, ultimately, patients. ResMed's moat, as per the GoodMoat framework, is built on several pillars. It demonstrates strong **Switching Costs** (criteria #2), as patients are fitted for specific masks and machines, creating a 'razor-and-blade' model with recurring mask sales. Its **Proprietary Data** (#3) from millions of connected devices provides insights that improve therapy and create a sticky ecosystem. It also holds **Regulatory Barriers** (#5) through the FDA approval process for medical devices. The company's **Technology Leadership** (#9) in quiet, comfortable devices and its integrated **Software** platform further protect its position. Key risks (Section 5 Red Flags) include **Competitive Erosion** (#8) from rival Philips and potential new entrants, and **Regulatory Risk** (#7) from changes in healthcare reimbursement policies. A value investor would note the company's exceptional fundamentals, including a 24.9% ROE (exceeding the 15-20% high-quality threshold), a strong 32.7% operating margin, and a healthy balance sheet with low debt. However, the current P/E of 22.4x and a price near $228, versus the GoodMoat target of $331, suggests the stock is trading at a premium, likely requiring perfect execution to justify. The 5.0% FCF yield is solid but not exceptional for a value entry point. Analysis based on data as of 2024-05-15.